Abstract
To investigate the antitumor effect of bromophenol derivatives in vitro and Leathesia nana extract in vivo, six bromophenol derivatives 6-(2,3-dibromo-4,5-dihydroxybenzyl)-2,3-dibromo-4,5-dihydroxy benzyl methyl ether (1), (+)-3-(2,3-dibromo-4,5-dihydroxyphenyl)-4-bromo-5,6-dihydroxy-1,3-dihydroisobenzofuran (2), 3-bromo-4-(2,3-dibromo-4,5-dihydroxybenzyl)-5-methoxymethyl-pyrocatechol (3), 2,2′,3,3′-tetrabromo-4,4′,5,5′-tetrahydroxy-diphenylmethane (4), bis(2,3-dibromo-4,5-dihydroxybenzyl) ether (5), 2,2′,3-tribromo-3′,4,4′,5-tetrahydroxy-6′-ethyloxymethyldiphenylmethane (6) were isolated from brown alga Leathesia nana, and their cytotoxicity were tested by MTT assays in human cancer cell lines A549, BGC-823, MCF-7, B16-BL6, HT-1080, A2780, Bel7402 and HCT-8. Their inhibitory activity against protein tyrosine kinase (PTK) with over-expression of c-kit was analyzed also by ELISA. The antitumor activity of ethanolic extraction of Leathesia nana (EELN) was evaluated on S180-bearing mice. All compounds showed very potent cytotoxicity against all of the eight cancer cell lines with IC50 below 10 μg/mL. In PTK inhibition study, all bromophenol derivatives showed moderate inhibitory activity and compounds 2, 5 and 6 showed significant bioactivity with the inhibition ratio of 77.5%, 80.1% and 71.4%, respectively. Pharmacological studies reveal that EELN could inhibit the growth of Sarcoma 180 tumor and increase the indices of thymus and spleen to improve the immune system remarkably in vivo. Results indicated that the bromophenol derivatives and EELN can be used as potent antitumor agents for PTK over-expression of c-kit and considered in a new therapeutic strategy for treatment of cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arber, D. A., R. Tamayo and L. M. Weiss, 1998. Paraffin section detection of the c-kit gene production (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum. Pathol. 28: 498–504.
Bliss, C., 1935. The calculation of the dose-mortality curve. Ann. Appl. Biol. 22: 134–167.
Bokemeyer, C., M. A. Kuczyk, T. Dunn et al., 1996. Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumors. J. Cancer Res. Clin. Oncol. 122: 301–306.
Carmichael, J., W. G. DeGraff, A. F. Gazdar et al., 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47(4): 936–942.
Christiansen, D. H., M. K. Andersen, F. Desta et al., 2005. Mutations of genes in the receptor tyrosine kinase (RTK)/RASBRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 19(12): 2 232–2 240.
d’Auriol L., M. G. Mattei, C. Andre et al., 1988. Localization of the human c-kit protooncogene on the q11–q12 region of chromosome 4. Hum. Genet. 78: 374–376.
de Silva, C. M. and R. Reid, 2003. Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol. Oncol. Res. 9(1): 13–19.
DeMatteo, R. P., 2002. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann. Surg. Oncol. 9(9): 831–839.
Demetri, G. D. 2001. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin. Oncol. 28(5): 19–26.
Fan, X., N. J. Xu and J. G. Shi, 2003a. Bromophenols from the red agla Rhodomela confervoides. J. Nat. Prod. 66: 455–458.
Fan, X., N. J. Xu and J. G. Shi, 2003b. Two new bromophenols from red alga Rhodomela confervoids. Chin. Chem. Lett. 14(9): 939–941.
Fan, X., N. J. Xu and J. G. Shi, 2003c. A new brominated phenylpropylaldehyde and its dimethyl acetal from red alga rhodomela confervoides. Chin. Chem. Lett. 14(10): 1 045–1 047.
Hirota, S., T. Nishida, K. Isozaki et al., 2002. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of Kit gene. Gastroenterology. 122(5):1 493–1 499.
Huang, Z. G. 1994. Marine Species and Their Distributions in China’s Seas. China Ocean Press, Beijing, China. p. 217. (in Chinese)
Ikeda, H., Y. Kanakura, T. Tamaki, et al., 1991. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78(11): 2 962–2 968.
Longley, J. B., D. D. Metcalfe, M. Tharp, et al., 1999. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA. 96(4): 1 609–1 614.
Majumder, S., K. Brown, F. H. Qiu et al., 1988. C-kit protein, a transmembrane identification in tissues and characterization. Mol. Cell Biol. 8: 4 896–4 903.
McCulloch, E. A. and M. D. Minden, 1993. The cell surface receptor encoded by the proto-oncogene KIT and its ligand. Cancer Treat Res. 64: 45–77.
Miettinen, M. and J. Lasota, 2005. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol. 13(3): 205–220.
Mosumann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1): 55–63.
Pietsch, T., M. R. Nicotra, R. Fraioli et al., 1998. Expression of the c- Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int. J. Cancer. 75(2): 171–175.
Sarlomo-Rikala, M., A. J. Kovatich, A. Barusevicius et al., 1998. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol. 11(8): 728–734.
Schmandt, R. E., R. Broaddus, K. H. Lu et al., 2003. Expression of c- ABL, c-KIT, and platelet-derived growth factor receptorbeta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98(4): 758–764.
Tajima, F., T. Kawatani, K. Ishiga et al., 1998. Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia. Eur. J. Haematol. 60: 289–296.
Vitali, R., V. Cesi, M. R. Nicotra et al., 2003. C-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int. J. Cancer 106(2): 147–152.
Vliagoftis, H., A. S. Worobec and D. D. Metcalfe, 1997. The protooncogene c-kit and c-kit ligand in human disease. J. Allergy. Clin. Immunol. 100(4): 435–440.
Xu, N. J., X. Fan, X. J. Yan et al., 2003. Antibacterial bromophenols from the marine red alga Rhodomela confervoids. Phytochemistry 62: 1 221–1 224.
Xu, X. L., F. H. Song, S. J. Wang et al., 2004a. Dibenzyl Bromophenols with Diverse Dimerization Patterns from the Brown Alga Leathesia nana. J. Nat. Prod. 67(10): 1 661–1 666.
Xu, X. L., X. Fan, F. H. Song et al., 2004b. A new bromophenol from the brown alga Leathesia nana. Chin. Chem. Lett. 15(6): 661–663.
Zhao, J. L, X. Fan, S. J. Wang et al., 2004. Bromophenol derivatives from the red alga Rhodomela confervoids J. Nat. Prod. 67: 1 032–1 035.
Zhao, J. L, M. Ma, S. J. Wang et al.,2005. Bromophenols coupled with derivatives of amino acids and nucleosides from the red alga Rhodomela confervoids J. Nat. Prod. 68: 691–694.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by the National High Technology Research and Development Program of China (863 Program, No. 2007AA09Z410) and Knowledge Innovation Program of Chinese Academy of Sciences (No. KZCX2-YW-209)
Rights and permissions
About this article
Cite this article
Shi, D., Li, J., Guo, S. et al. The antitumor effect of bromophenol derivatives in vitro and Leathesia nana extract in vivo . Chin. J. Ocean. Limnol. 27, 277–282 (2009). https://doi.org/10.1007/s00343-009-9119-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00343-009-9119-x